Army resigned from DLA Piper Friday, according to the New York Times, under pressure from DLA Piper's drug clients who are embarrassed at Armey's activities.
Sanofi spent $60,000 with DLA Piper this year, according to the Center for Responsive Politics lobbying database. Sanofi has much at stake if healthcare reform allows Medicare Part D to negotiate drug prices: Sanofi earned $137 million in annual windfall revenues from higher drug prices under Medicare, according to a Congressional report.
It was clear that Armey's presence at DLA Piper was becoming troublesome for BMS and its other clients; BNET received phone calls and a statement Thursday from the pair insisting that it was inaccurate to say that Armey and FreedomWorks were acting at BMS or DLA Piper's request. BNET noted that even if that was the case, the mere appearance of funding moving from BMS (and Sanofi) to DLA Piper, which employed Armey, who controls FreedomWorks, was unattractive.
- BMS, DLA Piper Distance Selves From Healthcare Town Hall Disruptions
- UPDATED: BMS Funded Anti-Reform Group But Its Execs Keep Health Coverage After Layoffs
- The Dog Ate My Homework: Medicines Co. Lobbied Against Deadlines, Not Healthcare Reform
- UPDATED: BMS Had $400M Motive to Use Healthcare Town Hall Rioters
- Claim: BMS, The Medicines Co., Funded Healthcare Town Hall Riot Group
- Amgen, GSK Lobby on Healthcare as Execs Enjoy Luxury Benefits
- As Lilly, Pfizer Lobby Against Obama Healthcare Plan, Their Execs Enjoy Gold-Plated Coverage
- Pharma Lobbying Money: Who's Spending What Fighting Healthcare Reform
- Lilly, Pfizer and AstraZeneca Jockeying for Position on Healthcare Reform
- Lilly CEO Lechleiter and PhRMA's Boogeyman: a "Government-Run Plan"
- Claim: AstraZeneca CEO Brennan's Pay Too High; Spends Too Much on Lobbying
- Drug Makers Gave Lobbyists an Xmas Gift -- Millions More to Lobby Obama Administration